| 前收市價 | 56.34 |
| 開市 | 56.34 |
| 買盤 | 56.10 x 1000 |
| 賣出價 | 56.78 x 800 |
| 今日波幅 | 56.18 - 56.61 |
| 52 週波幅 | 31.45 - 60.20 |
| 成交量 | |
| 平均成交量 | 2,745,072 |
| 市值 | 10.225B |
| Beta 值 (5 年，每月) | 1.19 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -7.18 |
| 業績公佈日 | 2024年5月17日 - 2024年5月21日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 56.70 |
ReutersUS FTC seeks more information on Novo Nordisk parent-Catalent deal
Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
- Reuters
UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. FTC has sought more information on Novo Nordisk parent's $16.5 billion bid for contract drug manufacturer Catalent, weeks after an application to the regulator was refiled for approval of the deal. Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
Insider MonkeyHow Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
